# Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome

> **NCT05087589** · PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT05087589
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-20
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05087589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05087589, "Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05087589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*